Flowflex COVID-19 Testing Age Restriction
The Flowflex rapid antigen test is authorized for individuals 2 years and older primarily due to lack of validated performance data in younger children, particularly those under 6 months of age, where test accuracy remains poorly understood and these vulnerable infants cannot mask or receive currently available COVID-19 vaccines. 1
Evidence Gaps in Very Young Children
The Infectious Diseases Society of America (IDSA) explicitly identifies a critical knowledge gap regarding antigen testing performance in very young children:
- Performance of antigen testing in children under 6 months of age is poorly understood, which is particularly concerning since these infants cannot mask and are ineligible for currently available COVID-19 vaccines 1
- The lack of clinical validation data in infants and very young children prevents manufacturers from extending authorization to this age group 1
- During October 2023–May 2024, infants under 6 months had the second-highest COVID-19 hospitalization rates after adults ≥75 years, making accurate testing in this population critically important 2
Practical Testing Considerations in Young Children
The 2-year age cutoff reflects practical specimen collection challenges:
- Nasal self-sampling or parent-assisted sampling in children under 2 years is technically difficult and may yield inadequate specimens, leading to false-negative results 3
- Proper swab insertion depth and technique cannot be reliably achieved in very young children who cannot cooperate with testing procedures 4
- The risk of inadequate specimen collection increases substantially below age 2, compromising test sensitivity 3
Test Performance Context
When Flowflex was evaluated during the Omicron period in symptomatic individuals ≥16 years:
- Overall sensitivity with nasal self-sampling was 79.0% (95% CI: 74.7% to 82.8%), which decreased to 80.9% as Omicron became the dominant variant 3
- Sensitivity was substantially higher (93.6%) in confirmatory testers who had previously tested positive, compared to only 52.4% in those testing for other reasons 3
- These performance characteristics cannot be extrapolated to children under 2 years without specific validation studies 1
Clinical Implications
For children under 2 years with suspected COVID-19:
- Standard NAAT (RT-PCR or laboratory-based nucleic acid amplification) should be used instead of rapid antigen tests for symptomatic children under 2 years 1
- NAAT has superior sensitivity (97%, 95% CI: 93% to 99%) compared to antigen testing and is the gold standard for diagnosis 1
- Testing should be performed within 5 days of symptom onset for optimal performance, regardless of test type 1
Regulatory and Safety Framework
The age restriction reflects standard regulatory requirements:
- FDA Emergency Use Authorization requires age-specific validation data before extending authorization to younger age groups 4
- Manufacturers must demonstrate adequate sensitivity and specificity in each age cohort before claiming performance in that population 5
- The 2-year threshold represents a pragmatic balance between clinical need and available validation data 3